
<DOC>
<DOCNO>WT03-B24-203</DOCNO>
<DOCOLDNO>IA064-000380-B023-150</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/allpart/allpart.htm 206.86.52.80 19970112101940 text/html 5244
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5062
Last-modified: Thu, 26 Sep 1996 23:59:17 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Alliances & Partnering</TITLE></HEAD>

<P>
<B><A HREF ="/BioCentury2/archive/1996/1qtr/031996ex.htm"> Behind the Athena-Elan deal </A></B><br>
This story describes the motivations behind the merger of Athena Neurosciences and Elan Corp. plc. March 19, 1996 (1,220 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/011596a1.htm"> Trading Technology </A></B><BR>
This article describes a new approach used by Sosei Co. Ltd. to link emerging technology in the U.S. and Europe with collaborators in Japan. Jan. 15, 1996 (1,900 words).<P>

<B><A HREF ="../../archive/1995/4qtr/1113a1.htm">How Arris and Khepri reached a merger </A></B><BR>
The planned merger of Khepri Pharmaceuticals Inc. into Arris Pharmaceutical Corp. reflects the critical choices facing early- to mid-stage biotechnology companies. This article discusses the factors of technology development, financing and strategy that the companies considered in deciding to merge their protease-based drug programs. Nov. 13, 1995 (1,100 words)

<B><A HREF ="../../archive/1995/4qtr/1023a1.htm">Partnering in Korea</A></B><BR>
Looking beyond Japan, companies in North America and Europe may be finding Korea as a potential market for biotech partnering. This article reviews transactions constructed in Korea by Aviron and Neoprobe Corp. It describes how Korea offers a market with its own history and its own business customs that biotech companies will need to learn before making deals. Oct. 23, 1995 (3,250 words)

<P>
<B><A HREF ="../../archive/1995/3qtr/0918a1.htm">Wishful thinking</A></B><BR>
Conflicting pressures involving both corporate collaborations and the demands of 
investors invite biotechnology companies to make their market size projections 
as large as possible. This article analyzes the problems this presents in reaching 
partnership deals. Sept. 18, 1995 (3,350 words)


<B><A HREF="../../archive/1995/2qtr/0626a1.htm">Amylin's New Deal</A></B><BR>
This story discusses Amylin Pharmaceuticals Inc.'s change of partners, aligning with Johnson & Johnson to cover the scientific and financial risk of getting its AC137 amylin agonist compound from Phase II trials through product launch in the diabetes area. Glaxo-Wellcome is out of scientific development but maintains an equity position in Amylin. 26.6.95 (1870 WORDS)<P>

<B><A HREF="../../archive/1995/2qtr/0605a1.htm">Pharma Partners for Biotech</A></B><BR>
In this story, pharmaceutical executives describe what they want to see from biotechnology companies as potential partners. Key is science, followed by intellectual property. (2575 WORDS). A related story,<A HREF="../../archive/1995/2qtr/0605a4.htm"> Explaining Valuations</A>, explains the difference between valuations in pharma deals vs. stock market offerings. 5.6.95 (650 WORDS)<P>


<B><A HREF="../../archive/1995/2qtr/0522b1.htm">Aviron Finds Korean Partner</A></B><BR>
This story explains the significance of Aviron's collaboration with Sang-A, a Korean pharmaceutical company and member of Hanbo group. The quickly concluded deal culminated a widening of the vaccine company's search partners. 22.5.95 (750 WORDS)<P>

<B>Chiron's Gene Therapy Efforts</B><BR>
These two stories describe Chiron's program to build its gene therapy program. The first story describes Chiron's access to <A HREF="../../archive/1995/2qtr/0410b1.htm">Progenitor Inc.'s </A> nonviral delivery and expressions systems. 10.4.95(550 WORDS)<P>

The second story discussed the terms and implications of Chiron's acquisition of <A HREF="../../archive/1995/2qtr/0425a1.htm">Viagene Inc. </A>25.4.95 (1250 WORDS)<P>

<B><A HREF ="../../archive/1995/1qtr/0306a3.htm">Isis: The Power Positioning Deal</A></B><BR>
The analysis reviews plans by Isis Pharmaceuticals Inc. and Boehringer Ingelheim International Gmbh to combine their R&D programs to focus on inflammatory diseases. Key is the ability to combine broad platform technologies or build disease management portfolios. 6.3.95 (1300 WORDS)<P>

<B><A HREF="../../archive/1995/1qtr/0213a1.htm">Reasons to Take Over Amgen</A></B><BR>
This story discusses the reaction of six leading Wall Street analysts to a frenzied week of trading of Amgen stock based on takeover rumors. They argue that the costs of the deal could outweigh benefits for the buyer and AMGN's shareholders. 13.2.95 (1900 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/home.html"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>